Doximity, Inc. DOCS
Composite 62/100; the shares have moved about 73% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 33/100 — a moderate mark against it.
Balance-sheet strength ranks 96/100 — a strong point in its favour. Quality ranks 77/100 — a strong point in its favour. Growth ranks 52/100 — a slight point in its favour.
Momentum ranks 33/100 — a moderate mark against it. Valuation ranks 44/100 — a slight mark against it.
What the company does Doximity operates a U.S. digital platform serving 2M+ medical professionals with workflow tools (Ask, Scribe), telehealth, and on-call scheduling (AMiON). Its monetization spans pharma sponsorships, health-system contracts, and premium subscriptions.
Key financials Doximity posts gross margin 89.1%, operating margin 21.6%, and net margin 30.4%. ROE 19.3%, ROA 11.6%, ROCE 25.8%. Revenue grew 5.1% YoY while EPS fell -69.0%. Debt/equity is 0.01 and current ratio 6.09.
Stock health Momentum is weak: -12.23% (3m), -45.16% (6m), -64.42% (12m), and -72.24% below its 52-week high. Sideravia scores Quality 76.4 and Strength 98.7 but Momentum only 10.0; RSI(14) is 49.20.
Price vs fair value The stock trades at a discount to both our fair-value estimate and analyst target. - Discount of 41.00% versus our fair-value estimate of 29.95 (Sideravia). - Discount of 15.87% versus the 12-month target of 24.61 based on 18.0 analysts (Sideravia). - Recent negative sentiment amplified by headlines highlighting underperformance versus the broader market (Zacks) and dismissive coverage (StockStory).
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.